Funding Condition. As of that Funding Date:
Funding Condition. If Tenant is unable to demonstrate to Landlord’s satisfaction, in Landlord’s reasonable discretion, that on or before the date which is one hundred twenty (120) days following the Lease Commencement Date, Tenant has raised an additional $20,000,000.00 or more in “Series A” or “Series B” funding (the “Funding Condition”), then Landlord shall have the ongoing right to terminate this Lease upon not less than forty-five (45) days prior written notice to Tenant (the “Funding Condition Termination”), which right must be exercised, if at all, prior to the earlier to occur of (i) the last day of the thirtieth (30th) month of the Lease Term and (ii) Tenant provides evidence to Landlord’s satisfaction, in Landlord’s reasonable discretion, that Tenant has satisfied the Funding Condition. [Blade Therapeutics, Inc.]
Funding Condition. Neither GE Capital nor Ares Capital Corporation (each an “Initial Lender”) shall be obligated to fund its commitment under the Term Loan unless Ares Capital Corporation (in the case of GE Capital) or GE Capital (in the case of Ares Capital Corporation) has complied with its obligations to Senior Secured Loan Fund, LLC (“SSLF”) such that SSLF, as permitted assignee, has funds sufficient to make the Term Loan (and each of GE Capital and Ares Capital Corporation commits and agrees with the Borrower to satisfy such obligations in full); provided, however, that nothing contained in this subsection (l) shall relieve GE Capital or Ares Capital Corporation from any liability, damages or remedies, including specific performance of the full amount of the commitments of both Initial Lenders, arising from any failure by GE Capital or Ares Capital Corporation, as the case may be, to comply with such obligations (including damages for relieving the other Initial Lender from its obligation to fund), and each of GE Capital and Ares Capital Corporation agrees that the Borrower (and its successors) shall be entitled to specific performance of each Initial Lender’s obligations to fund the Loans to the extent required by the terms hereof on the Closing Date; and
Funding Condition. “Funding Condition” shall have the meaning set forth in Section 8.3(d).
Funding Condition. Funding of subject loan contingent upon value of appraisal review & property inspection by principals.
Funding Condition. Parent and Newco shall have (i) received no less than $175,000,000 of debt financing as contemplated by the financing commitment of Bank of America, N.A., a copy of which has been provided to the Company, or (ii) obtained no less than such amount from another source on terms not materially less favorable to Parent and Newco than those contemplated by such commitment letter.
Funding Condition. This Agreement is based upon the parties’ assumption that funding for the work will be contributed to CFCI and all of CFCI’s obligations hereunder are conditioned upon receiving from the following sources, in the following amounts (“Third Party Funding”): Source Amount Insert if appropriate
Funding Condition. 2.1 Patobios’ right to require Omeros to purchase the MOCA Technology upon Omeros’ achievement of the De-Orphanization Milestone and Omeros’ obligation to purchase the MOCA Technology upon receipt of a Put Notice from Patobios, as set forth in Section 3.3 of the Agreement, shall be further conditioned on Omeros’ receipt of at least the Minimum Proceeds (as defined below) during the Option Period. Omeros will be deemed to have received the “Minimum Proceeds” for purposes of this Section 2.1 if the sum of the following amounts is at least equal to five million one hundred thirty five thousand ($5.135MM) CAD: (a) the amount of the Initial Patobios License Proceeds (as defined in Section 4.2 of this Amendment) that have been paid to Patobios by Omeros during the Option Period as provided in Section 4.3 of this Amendment (as converted into CAD on the dates that such proceeds were actually paid to Patobios); (b) the amount of any other funds that Omeros receives from governmental agencies or not-for-profit funding entities during the Option Period that are specifically allocated in the applicable funding document for the payment of the Acquisition Price by Omeros for the MOCA Technology (as converted into CAD as of the dates Omeros actually receives such funds) and (c) the De-Orphanization Milestone Payment. For purposes of clarity, the parties acknowledge that Omeros shall not be required to allocate, set aside or pay to Patobios any funds described in clause (b) of the preceding sentence until Omeros is deemed to have received the Minimum Proceeds. Throughout the term of this Agreement, Omeros shall with reasonable diligence use commercially reasonable efforts to raise the Minimum Proceeds and to source such further capital as may be necessary to enable Omeros to meet its obligations with respect to the Acquisition.
Funding Condition. The Agent understands that the Company requires funding for the Refinery Project in excess of the proceeds of the Offering, and has entered into subscription agreements with certain investors for the issuance of convertible notes with an initial principal amount of US$37.5 million, with an investor option to increase the principal amount of convertible notes by an additional US$7.5 million (the “Note Offering”). In addition to the terms and conditions described elsewhere herein, the completion of the Offering is conditional on the concurrent completion of the Note Offering (the "Funding Condition").
Funding Condition. In addition to the Funding Conditions set forth in the HSART Indenture, with respect to the Series 2012-VF1 Notes, the following additional “Funding Condition” shall apply:
